Golden Biotechnology Corp.

11:15 AM - 11:30 AM, Wednesday, October 23, 2019 ・ 2nd Floor
Golden Biotechnology Corporation (GBC), founded in 2002, is a leading innovative drug discovery and evidence-based healthy food supplement manufacturing company in Taiwan, dedicated to enhancing lives by developing high quality products that prevent and treat diseases.
In 2006, GBC discovered Antroquinonol® (trade name Hocena®), whose relevant therapeutic areas have been granted more than 120 patents worldwide for its structure, preparation method and best-in-class applications in oncology, cardio-metabolic syndromes, autoimmune diseases and neurodegenerative diseases.  
 
Oncology
· NSCLC Phase II in the USA. The results are published through ASCO in May 2019.
· Pancreatic cancer phase I/II in USA

Cardio-Metabolic Syndromes
· Hyperlipidemia phase II

Autoimmune Diseases
· Atopic Dermatitis phase II

Neurodegenerative Diseases
· Ongoing pre-clinical study on Alzheimer’s Disease in QUT, Australia under guidance of J&J
Ticker:
4312
Exchange:
OTC Taipei Exchange
Company Type:
Company HQ State:
Not Provided
Company HQ Country:
Taiwan
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Hocena
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Golden Biotechnology Corp.